Natalizumab for multiple sclerosis.

The New England journal of medicine ·Vol. 356 ·No. 25 ·2007-06-21 ·Pages 2622-9

Ransohoff RM

Abstract

暂无摘要

MeSH Terms

Adult Antibodies, Monoclonal/pharmacology,therapeutic use Antibodies, Monoclonal, Humanized Central Nervous System/immunology Female Humans Integrin alpha4 Leukocytes, Mononuclear/drug effects Multiple Sclerosis/drug therapy,immunology Multiple Sclerosis, Relapsing-Remitting/drug therapy Natalizumab

Chemicals

Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Natalizumab Integrin alpha4

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Ransohoff Richard M

Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute and Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, OH 44195, USA. ransohr@ccf.org

Article Info

Journal

The New England journal of medicine

Abbr.

N Engl J Med

ISSN

1533-4406

DOI

10.1056/NEJMct071462

ransohr@ccf.org

Published

2007-06-21

Pages

2622-9

Language

English

Region

United States

NLM ID

0255562

Subset

External Links

PubMed source DOI: 10.1056/NEJMct071462 View journal details

Analysis Services

Natalizumab for multiple sclerosis.

Contact

WeChat Official Account